Comparison
While BPC-157 is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects111, Thymosin Alpha-1 is clinically used in some countries as an immunomodulator for chronic hepatitis B/C and as an adjuvant in cancer therapy, enhancing cell-mediated immunity41487.
While BPC-157 works as a synthetic 15-amino-acid fragment of a gastric cytoprotective protein that promotes angiogenesis and tissue protection primarily by modulating VEGFR2 signaling, Src/caveolin-1–dependent eNOS activation, and nitric oxide production111, Thymosin Alpha-1 is a 28-amino-acid thymic peptide fragment of prothymosin alpha that activates dendritic cells and T cells primarily via TLR9/MyD88/NF-κB signaling, enhancing Th1 responses and NK-cell cytotoxicity414.
BPC-157 is 15 amino acids long, whereas Thymosin Alpha-1 is longer as it has a length of 28 amino acids. BPC-157 is made up of a sequence of Glycine, Glutamic acid, Proline, Proline, Proline, Glycine, Lysine, Proline, Alanine, Aspartic acid, Aspartic acid, Alanine, Glycine, Leucine, Valine. Thymosin Alpha-1 is made up of a sequence of Serine, Aspartic acid, Alanine, Alanine, Valine, Aspartic acid, Threonine, Serine, Serine, Glutamic acid, Isoleucine, Threonine, Threonine, Lysine, Aspartic acid, Leucine, Lysine, Glutamic acid, Lysine, Lysine, Glutamic acid, Valine, Valine, Glutamic acid, Glutamic acid, Alanine, Glutamic acid, Asparagine.
BPC-157
Not assigned in the current dataset.
Thymosin Alpha-1
PTMA